Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Tax Provisions came in at $1.2 billion in Q2 2026, up 27.15% year-over-year from $954.0 million in Q2 2025, and up 60.66% quarter-over-quarter from $755.0 million in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Tax Provisions across 18 years of filings, most recently posting $1.2 billion for Q2 2026.
- In Q2 2026, Tax Provisions rose 27.15% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $4.2 billion (down 11.25% YoY), while the FY2025 annual figure was $5.8 billion, up 120.41% from the prior year.
- Tax Provisions came in at $1.2 billion for Q2 2026 at Johnson & Johnson, up from $755.0 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $2.6 billion in Q1 2025 to a low of -$796.0 million in Q2 2023.
- Average Tax Provisions over 5 years is $883.0 million, with a median of $885.0 million recorded in 2022.
- Year-over-year, Tax Provisions slumped 211.64% in 2023 and soared 473.42% in 2025.
- Over 5 years, Tax Provisions stood at $862.0 million in 2022, then slipped by 19.49% to $694.0 million in 2023, then plunged by 34.29% to $456.0 million in 2024, then tumbled by 132.89% to -$150.0 million in 2025, then surged by 908.67% to $1.2 billion in 2026.
- Per Business Quant data, the three most recent Tax Provisions figures were $1.2 billion in Q2 2026, $755.0 million in Q1 2026, and -$150.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -1.01 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -407.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -524.23 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 165.91 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 39.70 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 17.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 1.21 Bn |
| Mar 29, 2026 | 755.00 Mn |
| Dec 28, 2025 | -150.00 Mn |
| Sep 28, 2025 | 2.34 Bn |
| Jun 29, 2025 | 954.00 Mn |
| Mar 30, 2025 | 2.63 Bn |
| Dec 29, 2024 | 456.00 Mn |
| Sep 29, 2024 | 644.00 Mn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 459.00 Mn |
| Dec 31, 2023 | 694.00 Mn |
| Oct 1, 2023 | 908.00 Mn |
| Jul 2, 2023 | 930.00 Mn |
| Apr 2, 2023 | -796.00 Mn |
| Jan 1, 2023 | 1.19 Bn |
| Oct 2, 2022 | 862.00 Mn |
| Jul 3, 2022 | 1.03 Bn |
| Apr 3, 2022 | 713.00 Mn |
| Oct 3, 2021 | 182.00 Mn |
| Jul 4, 2021 | 384.00 Mn |